Charley's Fund, Inc.

Charley’s Fund’s sole mission is to fund research to find a cure or treatment for Duchenne Muscular Dystrophy (DMD). We focus on funding translational research – research that moves science from the laboratory into human clinical trials so that it can have a measurable impact on boys who suffer from DMD now. Our secondary goal is to identify existing drugs that can keep DMD boys as healthy and strong as possible so they will still be able to benefit when the new drugs are ready for them. DMD is the number one genetic killer of children around the world and is 100% fatal. Our ultimate goal is to cure DMD in time to save the lives of thousands. Charley’s Fund was founded in 2004 by Tracy and Benjamin Seckler four months after their son Charley was diagnosed with deadly disease. As a result of their commitment to find a cure, groundbreaking new therapies are being developed.

Our strategy is to target problems and effect solutions, working quickly and without a long bureaucratic process. We direct money into the hands of researchers who have the best shot at developing a cure or treatment for DMD. Over the past five years Charley’s Fund has initiated new research with academic and industry partners around the globe. We have also fast-tracked research that was already underway so it is now on a timeline that could save of the lives of this generation of children with DMD. Since inception, Charley’s Fund has committed more than $15 million to medical research.